# Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
Canonical URL: https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-release-first-quarter-of-fiscal-year-2026-financial--0b19da78
Ticker: APYX
Company: Apyx Medical
Source: Apyx Medical
Published: 2026-04-23 12:00 EST
## Summary

Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical...

## Article Body
Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion ® and the AYON Body Contouring System ™ (AYON), today announced that its financial results for the first quarter of fiscal year 2026 will be released before markets open on Thursday, May 7 th .

Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 7 th , to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81537. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference.

About Apyx Medical Corporation :

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion ® and the AYON Body Contouring System ™ in the cosmetic surgery market and J-Plasma ® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com .

Investor Relations Contact : Jeremy Feffer Managing Director LifeSci Advisors OP: 212-915-2568 jfeffer@lifesciadvisors.com
## Recent Company News
- 2026-07-28 12:00 EST — [Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-participate-in-the-canaccord-genuity-46th-annual-gro-94590452) — Source: Apyx Medical
- 2026-07-23 12:00 EST — [Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-release-second-quarter-of-fiscal-year-2026-financial-0275b558) — Source: Apyx Medical
- 2026-05-21 12:00 EST — [New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®](https://biopharmsignal.com/news/APYX/new-study-shows-significant-improvement-in-cellulite-and-skin-laxity-with-advanc-d19ed0bc) — Source: Apyx Medical
- 2026-05-14 12:00 EST — [Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-announces-retrospective-clinical-publication-evaluating-065196d3) — Source: Apyx Medical
- 2026-05-11 12:00 EST — [Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-receives-expanded-fda-510-k-clearance-adding-power-lipo-c64ec7c1) — Source: Apyx Medical
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)